Genomic TestingBreast Cancer IndexAdjuvant OnlineGenomic Grade IndexMammaPrintMolecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are...
Consequently, clinically high-risk tumours (=43) were more frequently high-risk by EndoPredict than by MammaPrint (76.6% vs. 46.5%,=0.004), with 44% of cases discordantly classified and no significant association between genomic risk predictions (=0.294). Clinicians need to be aware that ...
RNAGene expression testing – These tests study mRNA in the cells to determine activity of different genes.MammaPrint®, Oncotype DX® Breast Reverse transcriptase PCR – Reverse transcriptase is an enzyme that converts RNA into DNA which is then detected by conventional PCR.Detection of specific...
Other examples of successful reimbursement of molecular diagnostics in oncology include Oncotype DX®, MammaPrint®, and OncoVue® (breast cancer); EGFR mutation assays (non-small cell lung cancer); BCR-ABL testing (chronic myelogenous leukemia); and others. HIV The HLA-B*5701 molecule is ...
There are various molecular testing assays such as Mammaprint31, BluePrint38, and Oncotype DX39, which have been well established and already applied in clinical practice. However, MammaPrint, and Oncotype DX are prognostic tools for prediction of high-, (intermediate-), and low-risk of recurrenc...
In addition, molecular classifiers such as Oncotype DX and GGI [33] and the MammaPrint (Agendia, Amsterdam, The Netherlands), the last of which is recommended to all patients, have negligible discriminatory power in ER-negative disease [30, 33]. Therefore, we believe that treatment decisions ...
To better understand how expedited genomic results could impact peri-operative care, we performed a pre-operative quality project to assess testing Mammaprint (MP), a 70-gene risk of recurrence assay, and Blueprint (BP), an 80-gene molecular subtyping assay, on core biopsies. Here we report ...
Results: Results indicate that of the 170 individuals who were tested through Agendia's MammaPrint and BluePrint panels and underwent germline genetic testing, 80 (46.47%) were classified as High-Risk for recurrence on MammaPrint, and 90 (53.53%) were identified as having a Low-Risk for ...
Ann Oncol 30(10):1541–1557 Cardoso F, van't Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J-Y et al (2020) MINDACT: long- term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adju- vant chemotherapy in breast cancer ...
Assi H, Bou Zerdan M, Ibrahim M, El Nakib C, Hajjar R (2020) Genomic Assays in Node Positive Breast Cancer Patients: A Review. Front Oncol 10:3461 Google Scholar Slodkowska EA, Ross JS (2009) MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast ca...